Core Insights - The stock price of Sely Medical (603716) increased by 2.92% to 25.0 CNY as of October 31, 2025, with a market capitalization of 5.254 billion CNY [1] Shareholder Changes - As of September 30, 2025, the number of shareholders reached 79,300, an increase of 33,600 or 73.49% compared to June 30, 2025 [3][6] - The average number of shares held per shareholder decreased from 4,180 to 2,651 shares, with an average holding value of 65,900 CNY [3] Performance Disclosure - For the first three quarters of 2025, the main revenue was 857 million CNY, a year-on-year decrease of 39.64% [4][6] - The net profit attributable to shareholders was -87.2441 million CNY, down 55.72% year-on-year [4][6] - The net profit excluding non-recurring items was -103 million CNY, a significant decline of 292.71% [4] - In Q3 2025, the single-quarter main revenue was 274 million CNY, a year-on-year decrease of 38.41% [4] - The single-quarter net profit attributable to shareholders was -31.1249 million CNY, an increase of 39.27% year-on-year [4] - The single-quarter net profit excluding non-recurring items was -31.9451 million CNY, down 58.6% year-on-year [4] - The company's debt ratio stood at 49.61%, with investment income of 7.3433 million CNY and financial expenses of 34.9823 million CNY, while the gross profit margin was 21.73% [4] Company Announcements - On October 29, 2025, the fifth board of directors held its 22nd meeting, where both the Q3 report and the asset impairment provision were approved unanimously [5][6]

Core Insights - The pharmaceutical commercial sector saw a rise of 0.42% on October 31, with HeFu China leading the gains [1] - The Shanghai Composite Index closed at 3954.79, down 0.81%, while the Shenzhen Component Index closed at 13378.21, down 1.14% [1] Stock Performance - HeFu China (603122) closed at 9.79, up 10.00% with a trading volume of 495,400 shares and a transaction value of 479 million [1] - RunDa Medical (603108) closed at 16.87, up 6.50% with a trading volume of 479,200 shares and a transaction value of 792 million [1] - SaiLi Medical (603716) closed at 25.00, up 4.82% with a trading volume of 267,700 shares and a transaction value of 664 million [1] - Other notable performers include First Pharmaceutical (600833) up 4.79% and GuoFa Co. (600538) up 4.36% [1] Capital Flow - The pharmaceutical commercial sector experienced a net inflow of 10.53 million from institutional investors, while retail investors saw a net inflow of 61.38 million [2] - However, speculative funds recorded a net outflow of 71.91 million [2] Individual Stock Capital Flow - RunDa Medical (603108) had a net inflow of 11.1 million from institutional investors, but a net outflow of 66.63 million from speculative funds [3] - SaiLi Medical (603716) saw a net inflow of 32.35 million from institutional investors, with a net outflow of 27.53 million from speculative funds [3] - GuoFa Co. (600511) had a net inflow of 18.53 million from institutional investors, while retail investors experienced a net outflow of 16.86 million [3]

Group 1 - The core point of the news is that Selys Medical experienced a stock price increase of 5.24%, reaching 25.10 CNY per share, with a trading volume of 400 million CNY and a turnover rate of 7.74%, resulting in a total market capitalization of 5.275 billion CNY [1] - Selys Medical Technology Group Co., Ltd. is located in Wuhan, Hubei Province, established on February 23, 2004, and listed on October 31, 2016. The company's main business includes centralized marketing and service for medical testing, agency for in vitro diagnostic products, and research, production, and sales of self-developed in vitro diagnostic products [1] - The revenue composition of Selys Medical is as follows: IVD business accounts for 39.91%, SPD business for 38.01%, and pure sales for 22.08% [1] Group 2 - From the perspective of fund holdings, one fund under Caitong Securities Asset Management has a significant position in Selys Medical. The Caitong Asset Management Healthcare Mixed A Fund (018484) held 200,000 shares in the third quarter, representing 5.72% of the fund's net value, ranking as the tenth largest holding [2] - The Caitong Asset Management Healthcare Mixed A Fund (018484) was established on August 3, 2023, with a latest scale of 64.306 million CNY. Year-to-date returns are 26.17%, ranking 3675 out of 8154 in its category; the one-year return is 25.68%, ranking 3563 out of 8046; and since inception, the return is 11.84% [2]

Core Viewpoint - Seer Medical is a leading enterprise in the domestic medical testing centralized service sector, established in 2004 and listed on the Shanghai Stock Exchange in 2016, with a comprehensive service capability across the entire industry chain [1] Financial Performance - For Q3 2025, Seer Medical reported revenue of 857 million yuan, ranking 21st out of 24 in the industry, significantly lower than the top competitor Shanghai Pharmaceuticals at 215.07 billion yuan and second-place Jiuzhoutong at 119.33 billion yuan, as well as below the industry average of 29.22 billion yuan and median of 14.66 billion yuan [2] - The main business composition includes IVD business at 233 million yuan (39.91%), SPD business at 222 million yuan (38.01%), and pure sales at 129 million yuan (22.08%) [2] - The net profit for the same period was -79.15 million yuan, ranking 23rd out of 24, with a significant gap compared to Shanghai Pharmaceuticals' 5.986 billion yuan and Jiuzhoutong's 2.077 billion yuan, and below the industry average of 611 million yuan and median of 205 million yuan [2] Financial Ratios - As of Q3 2025, Seer Medical's debt-to-asset ratio was 49.61%, down from 63.47% year-on-year and below the industry average of 59.74%, indicating relatively good debt repayment capability [3] - The gross profit margin was 21.73%, up from 19.89% year-on-year and higher than the industry average of 13.11%, reflecting a certain advantage in profitability [3] Executive Compensation - The chairman of Seer Medical, Wen Wei, has a salary of 900,000 yuan for 2024, unchanged from 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 73.49% to 79,300, with an average holding of 2,650.98 shares, down by 36.58% [5] - Among the top ten circulating shareholders, notable changes include the sixth-largest shareholder, Caitong Advantage Industry Rotation Mixed A, increasing holdings by 584,800 shares, and new entries from Guangfa Healthcare Stock A and Caitong Science and Technology Theme Flexible Allocation Mixed [5]

Core Viewpoint - The company reported a significant decline in revenue and an increase in net losses for the third quarter of 2025, indicating ongoing financial challenges and the need for strategic transformation [1] Financial Performance - For the third quarter, the company's revenue was 274 million, a year-on-year decrease of 38.4% [1] - The net loss for the third quarter improved slightly to 31.12 million from a loss of 51.25 million in the same period last year [1] - Year-to-date revenue for 2025 was 857 million, down 39.6% compared to the previous year [1] - The net loss for the year-to-date period increased to 87.24 million from a loss of 56.03 million in the previous year [1] - Total assets as of the end of the third quarter were 2.09 billion, a decrease of 26.1% from the end of the previous year [1] - The company's net assets increased by 16.8% to 1.091 billion compared to the end of the previous year [1] Strategic Focus - The company is focusing on core business areas and optimizing its operational structure while undergoing a strategic transformation towards medical intelligence [1] - The decline in revenue and gross profit was attributed to the transfer of equity in some subsidiaries during the reporting period [1] - To enhance profitability, the company has strengthened cost control, resulting in a combined reduction of 18.54% in sales, management, and financial expenses [1] - The report indicated that the company recognized credit impairment losses, which impacted operating profits [1] Business Operations - The company's main business includes medical supply chain services and the research and sales of related products, aiming to provide efficient medical services and solutions to clients [1] - The company plans to continue optimizing its business structure and upgrading its operations to respond to market changes and industry challenges [1]

Core Viewpoint - The financial performance of Sely Medical (603716) has significantly declined in the first three quarters of 2025, with a notable drop in both revenue and net profit, leading to a negative outlook for the company [1][3]. Trading Information Summary - On October 29, 2025, Sely Medical's stock closed at 24.3 yuan, down 0.25%, with a turnover rate of 4.51% and a trading volume of 94,700 shares, resulting in a transaction amount of 230 million yuan [1]. - The main funds experienced a net outflow of 38.52 million yuan, accounting for 16.77% of the total transaction amount, while retail investors saw a net inflow of 48.24 million yuan, representing 21.01% of the total [1][3]. Financial Report Summary - For the first three quarters of 2025, Sely Medical reported a main revenue of 857 million yuan, a year-on-year decrease of 39.64%, and a net profit attributable to shareholders of -87.24 million yuan, down 55.72% year-on-year [1]. - In Q3 2025, the company recorded a single-quarter main revenue of 274 million yuan, a decline of 38.41% year-on-year, and a net profit of -31.12 million yuan, which is an increase of 39.27% compared to the previous quarter [1]. - The company’s debt ratio stands at 49.61%, with investment income of 7.34 million yuan and financial expenses of 349.82 million yuan, resulting in a gross profit margin of 21.73% [1]. Company Announcement Summary - On October 29, 2025, Sely Medical held the 22nd meeting of the fifth board of directors, where all nine directors were present, and no votes were against or abstained [2]. - The board approved the Q3 2025 report and the proposal for asset impairment preparation, both of which had been previously reviewed by the audit committee [2][3].

Group 1 - The company, Saily Medical, announced a credit impairment loss of 20.713 million yuan and an asset impairment loss of 760,800 yuan for the first three quarters of 2025, totaling 21.4738 million yuan, which will reduce the total profit for the same period by the same amount [1] - The impairment provisions made by the company have not been audited by an accounting firm, and the impact on the annual profit for 2025 will be determined based on the results of the annual audit [1] - For the year 2024, the company's revenue composition is 97.09% from commercial activities and 2.91% from industrial activities [1] Group 2 - As of the latest report, Saily Medical has a market capitalization of 5.1 billion yuan [2]

Group 1 - The core point of the article is that Saily Medical reported a significant decline in revenue and incurred a net loss in the third quarter of 2023 [1] Group 2 - For the first three quarters of 2025, the company's revenue was approximately 857 million yuan, representing a year-on-year decrease of 39.64% [1] - The net profit attributable to shareholders of the listed company was a loss of approximately 87.24 million yuan [1] - The basic earnings per share showed a loss of 0.44 yuan [1] - As of the report date, Saily Medical's market capitalization was 5.1 billion yuan [2]

Core Viewpoint - The company reported a significant decline in revenue and an increase in net loss for the third quarter of 2025 compared to the previous year [1] Financial Performance - The company achieved total operating revenue of 857 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 39.64% [1] - The net profit attributable to shareholders of the parent company was -87.2441 million yuan, which is a deterioration of 31.219 million yuan compared to the same period last year [1] - The basic earnings per share were -0.44 yuan [1]

| | | 本次董事会经过了适当的通知程序，会议的召集、召开和表决程序符合《公 司法》等相关法律法规和《公司章程》的规定，会议及通过的决议合法有效。 二、董事会会议审议情况 本次会议审议并通过如下议案： 塞力斯医疗科技集团股份有限公司 第五届董事会第二十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、董事会会议召开情况 塞力斯医疗科技集团股份有限公司（以下简称"公司"）2025 年 10 月 24 日以邮件方式发送第五届董事会第二十二次会议通知，会议于 2025 年 10 月 29 日在公司 A 栋 C 会议室以现场和通讯相结合的方式召开。本次会议应到董事 9 人，实到董事 9 人，会议由董事长温伟先生主持，公司全部高级管理人员列席了 会议。 （二）审议通过《关于 2025 年前三季度计提资产减值准备的议案》 本议案已经第五届董事会审计委员会 2025 年第三次会议审议通过，并同意 提交董事会审议。 具体内容详见刊登在上海证券交易所网站（www.sse.com.cn）上的《关于 2025 ...